Globeimmune Inc
OTC:GBIM
Globeimmune Inc
Revenue
Globeimmune Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Globeimmune Inc
OTC:GBIM
|
Revenue
$6.5m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Globeimmune Inc's Revenue?
Revenue
6.5m
USD
Based on the financial report for Dec 31, 2015, Globeimmune Inc's Revenue amounts to 6.5m USD.
What is Globeimmune Inc's Revenue growth rate?
Revenue CAGR 5Y
10%
Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Globeimmune Inc have been -24% over the past three years , 10% over the past five years .